Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy
Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapyF. Genre1, R. López-Mejías1, J.A. Miranda-Filloy2, B. Ubilla1, B. Carnero-López3, I. Gómez-Acebo4, R. Blanco1, R. Ochoa1, M. Arias-Bajo1, J. Rueda-Gotor1, J. Paz-Carreira5, C. González-Juanatey6, J. Llorca4, M.A. González-Gay1
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain; 2Rheumatology Division, Hospital Xeral-Calde, Lugo, Spain; 3Oncology Division, Hospital Del Bierzo, Ponferrada, León, Spain; 4Computational Biology, School of Medicine, University of Cantabria, IFIMAV, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain; 5Haematology Division, Hospital Xeral-Calde, Lugo, Spain; 6Cardiology Division, Hospital Xeral-Calde, Lugo, Spain. 1
ObjectiveTo determine whether circulating osteopontin (OPN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are increased compared with controls and to establish whether disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of atherosclerosis are potential determinants of circulating OPN levels in these patients.
MethodsWe assessed OPN serum concentrations in a series of 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy and 48 matched controls. OPN levels were measured immediately before and after an infliximab infusion, at time 0 and at time 120 minutes respectively. Correlations of OPN serum levels with clinical features, disease activity, systemic inflammation, metabolic syndrome and several biomarkers of atherosclerosis were assessed. Potential changes in OPN concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed.
ResultsAt the time of the study AS patients undergoing anti-TNF-α therapy had low disease activity (mean BASDAI 2.94) and they showed similar OPN serum levels to healthy controls. No differences in OPN levels according to the specific clinical features of the disease were seen. Also, no correlation between OPN concentration and insulin resistance and adipokines was observed. However, a positive correlation between OPN and angiopoietin-2 (Angpt-2) serum levels was found (r=0.397; p=0.04). In addition, a single infliximab infusion led to a marginal statistically significant reduction in OPN levels (24112.19±14608.73 pg/ml at time 0 versus 21806.62±11390.83 pg/ml at time 120’; p=0.05).
ConclusionOPN and Angpt-2 serum levels are correlated in non-diabetic AS patients undergoing TNF-α antagonist therapy.
Key wordsankylosing spondylitis, atherosclerosis, inflammation, anti-TNF-α antibody-infliximab, osteopontin
atherosclerosis, bone remodeling, as well as ...5 suggested a strong association between elevated ...(2004) Correlation of osteopontin protein expression...
atherosclerosis, bone remodeling, as well as ...5 suggested a strong association between elevated ...(2004) Correlation of osteopontin protein expression...
热门文档